Efficacy and Safety Evaluation of Ruscus Aculeatus L in Patients With Hemorrhoids

PHASE4RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

November 2, 2026

Conditions
Hemorrhoid
Interventions
DRUG

Neoven 225 mg capsules

Patients in this group will only use Neoven 225 mg capsules orally. There will be no signs or inscriptions on the capsules regarding their contents. The duration of the study is determined as 42 days. A total of 378 mg of total ruscogenin (ruscogenin/neoruscogenin mixture obtained by extraction method) will be taken orally using one Neoven capsule orally with meals twice a day. A total of 84 capsules will be given to the patients, and their use will be questioned by phone on the 7th and 14th days of the treatment and the number of uses will be checked at the end of the treatment. Failure to use all of the capsules will be considered as a criterion for exclusion from the study.

DRUG

Placebo

Patients in this group will only receive an oral placebo capsule designed for this study. There will be no signs or inscriptions on the capsules regarding their contents. The duration of the study is determined as 42 days. During this period, one placebo capsule will be taken orally twice a day with meals. A total of 84 capsules will be given to the patients, and their use will be questioned by phone on the 7th and 14th days of the treatment and the number of uses will be checked at the end of the treatment. Failure to use all of the capsules will be considered as a criterion for exclusion from the study.

Trial Locations (1)

Unknown

RECRUITING

Sultan Abdulhamid Training and Research Hospital, Istanbul

All Listed Sponsors
collaborator

Atabay Kimya Sanayi Ticaret A.S.

INDUSTRY

lead

Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

OTHER

NCT07128979 - Efficacy and Safety Evaluation of Ruscus Aculeatus L in Patients With Hemorrhoids | Biotech Hunter | Biotech Hunter